Literature DB >> 11159257

Is comparative cardiotoxicity of S(-) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca(2+) channels?

G Zapata-Sudo1, M M Trachez, R T Sudo, T E Nelson.   

Abstract

Cardiac toxicity can occur after accidental intravascular injection of bupivacaine. Racemic bupivacaine can inhibit both cardiac Na(+) and Ca(2+) channels, but the contribution of these actions to cardiac depression is not totally understood. We tested whether the effect of R(+) bupivacaine on cardiac electrical activity in isolated hearts and on L-type Ca(2+) channels (I(Ca-L)) in isolated cardiac myocytes could be responsible for its increased cardiotoxicity compared with S(-) bupivacaine. Cardiac electrical activity of spontaneously beating isolated hearts was recorded before and after exposure to increasing concentrations of R(+) and S(-) bupivacaine. An increase of the PR interval (80%) and the QRS duration (370%) by 10microM R(+) bupivacaine (80% and 370%) was significantly higher than for S(-) bupivacaine (25% and 200%, respectively). R(+) but not S(-) bupivacaine produced severe arrhythmias at concentrations larger than 2.5microM. The intensity of I(Ca-L) inhibition did not differ between bupivacaine isomers. At 0 mV, I(Ca-L) was irreversibly reduced by 40.2% +/- 8.8% and 51.4% +/- 3.8% in the presence of 10microM R(+) and S(-) bupivacaine, respectively. The arrhythmogenic effect of R(+) bupivacaine could not be explained by stereoselectivity on the I(Ca-L) inhibition. Thus, other mechanisms could contribute to the cardiac electrical and contractile dysfunction induced by R(+) bupivacaine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159257     DOI: 10.1097/00000539-200102000-00040

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine.

Authors:  Robert W Gristwood
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Oxidative modulation of marcaine and lekoptin in H9C2 rat myoblasts.

Authors:  Julita Kulbacka; Julita Bar; Agnieszka Chwilkowska; Malgorzata Dumanska; Malgorzata Drag-Zalesinska; Teresa Wysocka; Kamilla Stach; Iwona Bednarz; Mateusz Lugowski; Anna Marcinkowska; Andrzej Gamian; Jolanta Saczko
Journal:  Acta Pharmacol Sin       Date:  2009-02       Impact factor: 6.150

3.  Bupivacaine inhibits a small conductance calcium-activated potassium type 2 channel in human embryonic kidney 293 cells.

Authors:  Hongfei Chen; Zhousheng Jin; Fangfang Xia; Zhijian Fu
Journal:  BMC Pharmacol Toxicol       Date:  2021-03-12       Impact factor: 2.483

4.  Epinephrine reversed high-concentration bupivacaine-induced inhibition of calcium channels and transient outward potassium current channels, but not on sodium channel in ventricular myocytes of rats.

Authors:  Fuli Liu; Bingjing Wu; Yongjun Du; Yiquan Wu; Hongfei Chen; Fangfang Xia; Zhousheng Jin; Xuzhong Xu
Journal:  BMC Anesthesiol       Date:  2015-04-30       Impact factor: 2.217

5.  A review of local anesthetic cardiotoxicity and treatment with lipid emulsion.

Authors:  Emma Bourne; Christine Wright; Colin Royse
Journal:  Local Reg Anesth       Date:  2010-02-26

6.  Application of nanogel systems in the administration of local anesthetics.

Authors:  Jeremy Pk Tan; Maureen Bh Tan; Michael Kc Tam
Journal:  Local Reg Anesth       Date:  2010-09-01

7.  Lipid emulsions enhance the norepinephrine-mediated reversal of local anesthetic-induced vasodilation at toxic doses.

Authors:  Soo Hee Lee; Hui-Jin Sung; Seong-Ho Ok; Jongsun Yu; Mun-Jeoung Choi; Jin Soo Lim; Ju-Tae Sohn
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

8.  Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline.

Authors:  Kevin R DeMarco; Pei-Chi Yang; Vikrant Singh; Kazuharu Furutani; John R D Dawson; Mao-Tsuen Jeng; James C Fettinger; Slava Bekker; Van A Ngo; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Jon T Sack; Heike Wulff; Colleen E Clancy; Igor Vorobyov
Journal:  J Mol Cell Cardiol       Date:  2021-05-29       Impact factor: 5.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.